GlassScriptPhysician profile
David S Stevener
NPI 1609193721
$5,204.09
in general payments reported to CMS, 2019-2025
36 companies · $1,520 in 2025
The $1,520 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $17.42 · 2021: $222 · 2022: $179 · 2023: $1,476 · 2024: $1,491 · 2025: $1,520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,487.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $977.89 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $746.49 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $744.83 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $589.36 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $346.78 | 2023-2025 | |
| Axsome Therapeutics, INC. | $256.67 | 2024-2025 | Auvelity |
| Abbvie INC. | $254.99 | 2021-2025 | Vraylar, Ubrelvy |
| Janssen Pharmaceuticals, INC | $196.54 | 2019-2024 | Xarelto, Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.83 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $141.52 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $98.44 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Phathom Pharmaceuticals, INC. | $72.12 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $71.34 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $55.15 | 2019-2020 | |
| Inspire Medical Systems, INC. | $52.50 | 2025 | Inspire |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Stevener listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.